You are here:

rifaximin (Targaxan)

Advice

following a full submission

rifaximin (Targaxan®) is accepted for use  within NHS Scotland.

Indication under review: reduction in recurrence of episodes of overt hepatic encephalopathy (HE) in patients ≥18 years of age.

In a double-blind randomised controlled study of six months duration, rifaximin was superior to placebo for the primary outcome of time to first overt breakthrough episode of HE.

Drug Details

Drug Name: rifaximin (Targaxan)
SMC Drug ID: 893/13
Manufacturer: Norgine Ltd
Indication: Reduction in recurrence episodes of overt hepatic encephalopathy in patients 18 years or older.
BNF Category:
Sub Category: 5.1 Antibacterial drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 9 September 2013

Back